Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2018

08.08.2017 | Original Article

Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan

verfasst von: Sachi Morita, Toyone Kikumori, Nobuyuki Tsunoda, Takahiro Inaishi, Yayoi Adachi, Akiko Ota, Masahiro Shibata, Ayumu Matsuoka, Kenichi Nakanishi, Dai Takeuchi, Takefumi Mizutani, Tomoya Shimokata, Hironori Hayashi, Osamu Maeda, Yuichi Ando

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Dose-dense chemotherapy consisting of a combination of epirubicin and cyclophosphamide (EC) improves the survival of patients with breast cancer. Although pegfilgrastim was used at a subcutaneous dose of 6.0 mg in a pivotal study of dose-dense EC treatment, pegfilgrastim at a dose of 3.6 mg has been approved in Japan. We have assessed the feasibility of dose-dense EC treatment supported with a 3.6 mg dose of pegfilgrastim by evaluating the relative dose intensity (RDI) and safety of the treatment, together with measuring the pegfilgrastim concentrations remaining on the day of starting the next cycle of chemotherapy.

Methods

Patients with primary breast cancer received a total of 4 cycles of dose-dense EC treatment every 2 weeks, together with a subcutaneous injection of 3.6 mg pegfilgrastim on the day after chemotherapy. The serum granulocyte colony-stimulating factor (G-CSF) concentrations were measured on the 15th day of every chemotherapy cycle.

Results

From March 2015 through to July 2016, a total of 51 patients (median age 51 years; range 33–73 years) were studied. The mean RDI was 95.2% (range 60.0–100%). Although most adverse events were consistent with those reported in previous studies, pneumocystis pneumonia developed in two patients during the following course of docetaxel treatment. The median serum G-CSF concentration was 92.5 (range 30.4–440) pg/ml.

Conclusions

With support provided by pegfilgrastim injection at a dose of 3.6 mg, dose-dense EC is feasible and associated with maintenance of a high RDI. There was no clinically significant accumulation of serum G-CSF concentrations associated with the use of a 3.6 mg dose of pegfilgrastim at 2-week intervals.
Literatur
1.
Zurück zum Zitat Yamamoto N, Sekine I, Nakagawa K, et al. (2009) A pharmacokinetic and dose escalation study of pegfilgrastim (KRN 125) in lung cancer patients with chemotherapy-induced neutropenia. Jpn J Clin Oncol 39:425–430CrossRefPubMed Yamamoto N, Sekine I, Nakagawa K, et al. (2009) A pharmacokinetic and dose escalation study of pegfilgrastim (KRN 125) in lung cancer patients with chemotherapy-induced neutropenia. Jpn J Clin Oncol 39:425–430CrossRefPubMed
2.
Zurück zum Zitat Green MD, Koelbl H, Baselga J, et al. (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35CrossRefPubMed Green MD, Koelbl H, Baselga J, et al. (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35CrossRefPubMed
3.
Zurück zum Zitat Holmes FA, Johnes SE, O’Shaughnessy J, et al. (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909CrossRefPubMed Holmes FA, Johnes SE, O’Shaughnessy J, et al. (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909CrossRefPubMed
4.
Zurück zum Zitat Masuda N, Tokuda Y, Nakamura S, et al. (2015) Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer 23:2891–2898CrossRefPubMedPubMedCentral Masuda N, Tokuda Y, Nakamura S, et al. (2015) Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer 23:2891–2898CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Del Mastro L, De Placido S, Bruzzi P, et al. (2015) Fluorouracil and dose- dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomized phase 3 trial. Lancet 385:1863–1872CrossRefPubMed Del Mastro L, De Placido S, Bruzzi P, et al. (2015) Fluorouracil and dose- dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomized phase 3 trial. Lancet 385:1863–1872CrossRefPubMed
6.
Zurück zum Zitat Lambertini M, Bruzzi P, Poggio F, et al. (2016) Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. Support Care Cancer 24:1285–1294CrossRefPubMed Lambertini M, Bruzzi P, Poggio F, et al. (2016) Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. Support Care Cancer 24:1285–1294CrossRefPubMed
7.
Zurück zum Zitat Kris MG, Tonato M, Bria E, et al. (2011) Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 19:S25–S32CrossRefPubMed Kris MG, Tonato M, Bria E, et al. (2011) Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 19:S25–S32CrossRefPubMed
8.
Zurück zum Zitat Worth LJ, Dooley MJ, Seymour JF, et al. (2005) An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 92:867–872CrossRefPubMedPubMedCentral Worth LJ, Dooley MJ, Seymour JF, et al. (2005) An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 92:867–872CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Waks AG, Tolaney SM, Galar A, et al. (2015) Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat 154:359–367CrossRefPubMed Waks AG, Tolaney SM, Galar A, et al. (2015) Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat 154:359–367CrossRefPubMed
10.
Zurück zum Zitat Tolaney SM, Najita J, Winer EP, et al. (2008) Lymphopenia associated with adjuvant anthracycline/taxane regimens. Clin Breast Cancer 8:352–356CrossRefPubMed Tolaney SM, Najita J, Winer EP, et al. (2008) Lymphopenia associated with adjuvant anthracycline/taxane regimens. Clin Breast Cancer 8:352–356CrossRefPubMed
11.
Zurück zum Zitat Quartino AL, Karlsson MO, Lindman H, et al. (2014) Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling. Pharm Res 31:3390–3403CrossRefPubMed Quartino AL, Karlsson MO, Lindman H, et al. (2014) Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling. Pharm Res 31:3390–3403CrossRefPubMed
Metadaten
Titel
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan
verfasst von
Sachi Morita
Toyone Kikumori
Nobuyuki Tsunoda
Takahiro Inaishi
Yayoi Adachi
Akiko Ota
Masahiro Shibata
Ayumu Matsuoka
Kenichi Nakanishi
Dai Takeuchi
Takefumi Mizutani
Tomoya Shimokata
Hironori Hayashi
Osamu Maeda
Yuichi Ando
Publikationsdatum
08.08.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1177-z

Weitere Artikel der Ausgabe 1/2018

International Journal of Clinical Oncology 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.